Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q2 FY2020 Earnings Presentation
21 slides from Lincoln Pharmaceuticals's earnings presentation, 2019
Slide 1: Q2 FY2020 Earnings Presentation
Providing Affordable and Innovative medicines for healthier lives Q2 FY2020 Earnings Presentation 1 www.lincolnpharma.com
Slide 2: Highlights
Highlights Q2 FY2020 vs. Q1 FY2020 Management Perspective "We are pleased to report robust financial performance during the quarter. The o Total Income of Rs. 1,152 million, up 17.4% growth has been attributed to a strong performance in domestic and international markets. Our exports sales (FOB) inc
Slide 3: Performance Overview
Performance Overview Consolidated Financial Performance Q2 y-o-y Q1 q-o-q Half Year y-o-y Particulars FY2020 FY2019 Growth (%) FY2020 Growth (%) FY2020 FY2019 Growth (%) Net Revenue 1,152.1 1,070.4 7.6% 981.1 17.4% 2,133 2,092 2.0% EBITDA 272.0 235.2 15.7% 203.4 33.7% 475 491 (3.2)% Margin (%) 23.6%
Slide 4: Revenue Breakup: Therapeutic Area and Geography
Performance Overview Revenue Breakup 4% 2% 3% 2% General Anti Infectives 9% 24% 21.0% 21.5% Respiratory Systems 22.1% Therapeutic Area 25.8% 14% Alimentary Tract and Metabolism Genito Urinary System and Sex Hormones 0.5% 0.1% 2.8% 13% 15% Musculo-Skeletal System 2.9% Q2 FY20 0.3% Q2 FY19 8.4% 14% Pa
Slide 5: Performance Trend
Performance Trend Total Income (Rs. million) and Y-o-Y Growth (%) 15.5% 15.4% (3.9)% 7.6% 2.2% 1,070.4 848.1 784.5 981.1 1,152.1 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 Q2 FY20 EBITDA (Rs. million) and Margin (%) 22.0% 23.6% 20.7% 16.5% 13.1% 235.2 139.9 103.1 203.4 272.0 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 Q2
Slide 6: Performance Trend
Performance Trend Net Debt / LTM EBITDA Total Debt / Net Worth 0.54x 0.18x 0.18x 0.47x 0.15x 0.36x 0.37x 0.13x 0.13x 0.14x Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 Q2 FY20 Q2 FY19 Q3 FY19 Q4 FY19 Q1 FY20 Q2 FY20 ROCE1 RONW2 24.3% 23.7% 21.6% 20.6% 19.6% 19.5% 18.8% 17.9% 17.7% 16.0% Q2 FY19 Q3 FY19 Q4 FY19 Q
Slide 7: Leverage Profile
Leverage Profile (Rs. million) Mar-2019 Sep-2019 Credit Rating Long Term Debt 17 5 o CRISIL Short Term Debt 301 362 Long term bank facilities: A-/Stable Total Debt 318 367 Short term bank facilities: A2+ o ICRA Less: Cash & Cash Equivalents 55 269 Long term bank facilities: A- Net Debt / (Net
Slide 8: Recent Developments
Recent Developments 1 Secured a patent for Diclofenac Rectal Spray • Recently the company has been awarded with a patent for its liquid Diclofenac Metered-Dose Rectal Spray (Diclofenac Rectal Spray) • The company has necessary approvals from Drug Controller General of India (DCGI) and planning to la
Slide 9: Recent Developments
Recent Developments 4 Amalgamation between Lincoln Parenteral Limited and Lincoln Pharmaceuticals Limited • Recently board of directors of the company approved the scheme of amalgamation between Lincoln Parenteral Limited ("Transferor Company") and Lincoln Pharmaceuticals Limited ("Transferee Compan
Slide 10: Research & Development
Research & Development Research Facilities R&D Expenditure (Rs. mn) and as % of Sales 4.0% 3.2% 2.4% 2.0% 2.7% 148.1 Senior Scientist 15 117.3 Junior Scientist 18 1.6% 88.5 Analysts 18 79.5 72.6 Regulatory Personnel 12 Administrative Personnel 9 34.3 Others 6 Total 78 FY14 FY15 FY16 FY17 FY18 FY19 Q
Slide 11: A Leading Pharmaceutical Company
A Leading Pharmaceutical Company Research & Development Department Market Presence Presence in Presence in 4 Patents granted 1,700 Registered products 60+ 25 25 Patents applications 700 in pipeline Countries States across India 300+ 72nd 15+ Formulations developed Rank in AIOCD Therapeutic areas 650
Slide 12: Key Milestones
Key Milestones Received WHO – Becomes Public Covered 80% Installed Windmill Developed & Launch 3 products which are Targeting Many New GMP for plant / Limited Company of all India 600 KVA launched 2 more first time in India. Entered in Countries in West Africa & production unit from a Partnership Ma
Slide 13: Global Footprint
Global Footprint Presence over 60 + Countries in Europe, Latin America, Africa, Asia Pacific, South East Asia and 25 States across India Jammu Uttaranchal Chandigarh Delhi Europe: Ambala Ghaziabad France Lucknow Guwahati Jaipur Patna Ranchi Ahmedabad Kolkata Indore Raipur Nagpur Cuttack Vijayawada C
Slide 14: Best in Class Facilities
Best in Class Facilities Certifications: WHO-GMP Certified; ISO 9001:2015 Certified R&D Center: Approved by Government of India; Team of 30 scientists for R&D Green Energy: Windmill project for captive consumption Dosage Forms Produced at Unit 1 Dosage Forms Produced at Unit 2 Description Annual Cap
Slide 15: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough & Cold / Sterile Ophthalmic Dermatologist Gyneacologial Gastro Intestinal Anti Allergic / Anti- Eye Preparation Products Range asthmatics Drops/Ointment Anti-bacterial / Vitamins / Minerals Analgesic / Anti- Anti-diuretics/ Anti-malarial Anti-viral/ Anti-
Slide 16: Key Brands
Key Brands Domestic Market International Market Calcium Carbonate 1250 mg+ 11 Antioxidants + 33 Essential Micronutrients + Each squirts (spray) delivers 2 α-β Arteether Injection Vit. D3 250 I.U. Tablets 5 Amino Acids mg Ondansetron Hydrochloride 150mg/ 2 ml Effective Anti- Malarial Kingping Heparin
Slide 17: Key Developments
Key Developments o Progesterone spray • Unique delivery system for accurate 25mg delivery of micronized progesterone/Spray • Formulation dispensed in mist form which provides local as well as systemic effect of Progesterone via vaginal route covering large area of vaginal cavity • Better patient com
Slide 18: Key Developments
Key Developments o Domi Up Spray • Meter dose pump • Each squirt (spray) accurately delivers 2 mg Ondansetron Hydrochloride • Faster onset of action • Prompt relief from nausea & vomiting • Convenient for patient over Injectable • Better patients compliance o Namcold DX • First time in India: ‘Exten
Slide 19: Key Developments
Key Developments o USP INFITY - HS • Revitalized the DPC • Covering all aspects of Baldness in one solution • Powered with the Hair Growth Formula • Empowered with Powerful Antioxidant than Vitamin E or Vitamin C Q2 FY2020 Earnings Presentation 19
Slide 20: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfor
Slide 21: Corporate Office
CORPORATE OFFICE LINCOLN HOUSE B/h. Satyam Complex, Science City Road, Sola, Ahmedabad – 380 060. Gujarat, INDIA. Phone :+91-79-4107 8000 • Fax:+91-79-4107 8062 E-mail: info@lincolnpharma.com www.lincolnpharma.com CIN: L24230GJ1995PLC024288 KP Sompura Finance Head, Lincoln Pharmaceuticals sompurakp@
Lincoln Pharmaceuticals — Q2 FY2020 Earnings Presentation on 6ix